-
-
-
-
-
-
-
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
-
-
-
-
-
-
-
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
-
-
-
-
-
15,768 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

